Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management - Wikidata - wikimedia - TriplyDB

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

http://www.wikidata.org/entity/Q35587435

about

Anaesthesia and airway management in mucopolysaccharidosis.The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure Aortic Root Dilatation in Mucopolysaccharidosis I-VII Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats.Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease The factors affecting lipid profile in adult patients with Mucopolysaccharidosis Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America.Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience.Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis I.Long-term functional outcomes of children with hurler syndrome treated with unrelated umbilical cord blood transplantation.Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome)Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients.Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI.Mucopolysaccharidosis Type II and the G374sp Mutation.Endothelial function in children and adolescents with mucopolysaccharidosis.Fatal and unanticipated cardiorespiratory disease in a two-year-old child with hurler syndrome following successful stem cell transplant.Pregnancy in patients with mucopolysaccharidosis: a case series Pathogenesis of mitral valve disease in mucopolysaccharidosis VII dogs.The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.Cardiovascular Abnormalities in Egyptian Children with Mucopolysaccharidoses.Carotid intima-media thickness is increased in patients with mucopolysaccharidoses.Current and emerging management options for patients with Morquio A syndrome Diagnostic approach and differential diagnosis in patients with hypertrophied left ventricles.Lysosomal storage diseases--the horizon expands.Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).Human-Induced Pluripotent Stem Cell-Based Modeling of Cardiac Storage Disorders.Hyaluronidase 2 Deficiency Causes Increased Mesenchymal Cells, Congenital Heart Defects, and Heart Failure.Mucopolysaccharidoses Causing Valvular Heart Disease: Report and Review of Surgical Management.Glycosaminoglycan metabolism defects and atherosclerosis: frequent association of endothelial dysfunction in patients with Mucopolysaccharidosis.Massive accumulation of glycosaminoglycans in the aortic valve of a patient with Hunter syndrome during enzyme replacement therapy.Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome.Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)Murine hyaluronidase 2 deficiency results in extracellular hyaluronan accumulation and severe cardiopulmonary dysfunction Mortality in patients with Sanfilippo syndrome.Cardiac manifestations in mucopolysaccharoidosis Management of difficult airway with laryngeal mask in a child with mucopolysaccharidosis and mitral regurgitation: a case report.Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

P2860

Q26996429-BDA9763D-FD4F-4C8B-8E8D-ED04BBA561FA Q28546251-066A7EB9-14CA-44B2-8755-E82ABBA80C4E Q30367116-77231A00-92DC-4D4C-AA79-E436C8F1C5F4 Q30513972-EC344F32-1956-4F4E-A105-1DBEF584B848 Q30583745-ADB4305D-D9D1-495F-AA0D-4A2550F2605B Q33716134-9D2A2CF2-B1D7-4DC5-86D3-80417F438B2E Q33800119-46D2954D-1D96-498B-990B-FF31E3836E72 Q33890337-E46E8052-3B0B-43F0-92DF-0A09967FE9B4 Q34311268-7968B109-F622-4DF8-9D72-D98344927E7E Q34457702-E8F3256C-BDE0-4F03-8D2B-1D54E509A48B Q35220724-3BAD8832-6F8E-4E7E-982E-21F486F6DC81 Q36127763-E8162A95-A2B7-444F-86C0-75A599F031CA Q36571573-0D2C31A8-76AA-41AC-A349-5D37F8EBBE5E Q36662835-F6ECDAED-4BEE-4A10-A528-09719BD9EFCC Q36883369-79F58D06-6CD9-4D40-9D7B-D0C20961C5C5 Q36934361-A17162B4-DFF4-4113-B28D-56C66893E12D Q37127672-9FCB2C75-79DB-48FC-BC5B-628299C2C0FA Q37224435-2CC3233D-7302-48B1-B3F0-BFBD8147AE4C Q37238697-B4620584-D9BC-4B3D-A7CA-AA0DC073D0CA Q37238895-BCDEB756-43CB-4937-B242-A2722037276F Q37507816-E9761E4D-88E4-4244-9A46-D66167AEC306 Q37543239-62C64811-0128-4A5C-BCD8-864AEE9049B0 Q37584874-B06477AE-04D9-4706-AF00-31843D39CBFC Q38081868-D7AD8C2B-AB4A-4799-9716-366DFAC21021 Q38103225-95DAA1B8-E82C-4644-8598-C683D5A6F854 Q38128478-366F53F1-1B99-40BF-BF31-EC2F6B33ED50 Q38246994-69A9C5A2-7F3D-426D-82A6-824A4B4563AC Q38751652-24F0CEBC-964C-4723-9FC4-84D852229A85 Q38961622-5BC00437-4EE1-4354-864C-D3414C9FC3DD Q39250206-AEE26F7B-8F40-410D-94B6-904978A00111 Q40127329-7D0EE416-F427-4A9C-9D9C-B3F010322B5D Q41827061-5CD859EF-AEE1-47C4-88DE-AB2D721BFECE Q41980873-3F3242F6-2A06-4236-B48D-CEC434F9FCA8 Q42176546-9261F99B-D74A-454B-9640-355B7E58ABAA Q42281140-C1A6E0C3-8DE8-4C34-9401-42E3961F774C Q42532970-20BC2488-9049-4038-B7B8-FAFCFE4CD1E3 Q42644024-67EC6D6D-70B2-44B1-8596-FDA1861F7FC0 Q42786507-F975260A-2E2B-4DD6-A1CB-2B1230990806 Q43053241-D750B1EF-F4D0-4CFE-89F7-24A2EEF6D27F Q45874778-20A3919B-FB5C-4D2F-A992-8F4B3FF69710

P2860

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

http://www.wikidata.org/entity/Q35587435

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Cardiac disease in patients wi ...... tion, diagnosis and management

@ast

Cardiac disease in patients wi ...... tion, diagnosis and management

@en

type

label

Cardiac disease in patients wi ...... tion, diagnosis and management

@ast

Cardiac disease in patients wi ...... tion, diagnosis and management

@en

prefLabel

Cardiac disease in patients wi ...... tion, diagnosis and management

@ast

Cardiac disease in patients wi ...... tion, diagnosis and management

@en

P1433

Q35587435-455D9389-E09B-4E4C-B975-D66F81CB4606

P1476

Q35587435-361209EB-FB98-4D22-BB58-E844055C0BD3

P2093

Q35587435-1425E22A-16C4-438B-8BB5-55EACD0341B8

Q35587435-20F36BF5-1D8E-4AF8-9B34-1748F5CC644C

Q35587435-26AF82D1-8213-49FD-94F3-CC6D57355D78

Q35587435-3CCCA060-A765-458C-9F0E-53879DB42392

Q35587435-4469697D-014E-42F0-8E81-FFCC55082D3E

Q35587435-54D4B502-B605-4302-AD74-820BF2D5EF6B

Q35587435-85652B87-160F-4E3A-81A0-5DA4CDE3AB83

Q35587435-889DEA42-20D3-45CE-8996-94A5FFD427BA

Q35587435-9331C8AA-8471-41EC-A910-D393C147D0E7

Q35587435-E5BDFD85-2B9B-4A20-919E-76CDAEAFC604

P2860

Q35587435-0083E374-CE5F-4B3E-9C23-379F66673090

Q35587435-02074071-157F-4E92-909A-2E428A3B151C

Q35587435-03445C0D-E00F-4740-8556-865EC741F18F

Q35587435-042D4974-85A9-44A7-9734-A0E0DDF85843

Q35587435-05957A88-10D6-4833-89EB-CA739002FC9B

Q35587435-091879BC-7D42-4699-886C-00E3177905B2

Q35587435-112F86BF-66F9-4B40-94C9-44B8DBE2E901

Q35587435-12CF8E90-34DE-47F8-8A54-48B1EAD7A8AD

Q35587435-145F7C12-7949-4030-AB86-BA33131FC222

Q35587435-16ABE481-DD19-47C9-B313-0706B150FB30

P2888

Q35587435-F96893CE-B851-4828-A804-9295E4A009A1

P304

Q35587435-D4BE94B7-2E73-4B40-A484-341FD7AEEC6A

P31

Q35587435-0F1DED61-9C53-494B-80AA-D4B656D0F9D7

Q35587435-F100988A-097F-4498-AF08-CFF18FB60E37

P356

Q35587435-5A27A387-CBB2-456A-9394-E0DA2FCB3366

P433

Q35587435-FE540B24-F175-4EE7-8B08-B544620BAC22

P478

Q35587435-AE88D6D8-0499-4E60-A6F5-355248547A77

P577

Q35587435-92BEFA2F-154E-4BED-A450-CAFF5BEB0D0C

Q35587435-EAE11502-F036-47F1-9D6D-894B17FDC79D

P5875

Q35587435-EF583CB9-E9B3-4604-9163-B3DDA98CDE0D

P698

Q35587435-A24BAAF4-FCD3-42CC-8D76-E2D3C0CA236A

P921

Q35587435-070B4EA5-78DE-4A48-98CA-244D81D37EEB

Q35587435-38A07EE0-FF61-4AFD-B8D2-1C7A4D42DDEB

Q35587435-3C7B3966-159E-48BA-B34F-DFF136E10197

P932

Q35587435-69A4700E-B68D-40C2-9ACC-D47422451200

P356

S10545-011-9359-8

P1433

Journal of Inherited Metabolic Disease

P1476

Cardiac disease in patients wi ...... tion, diagnosis and management

@en

P2093

Beatriz Furlanetto

http://www.w3.org/2001/XMLSchema#string

Christoph Kampmann

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Braunlin

http://www.w3.org/2001/XMLSchema#string

Howard M Rosenfeld

http://www.w3.org/2001/XMLSchema#string

James P Loehr

http://www.w3.org/2001/XMLSchema#string

Katherine P Ponder

http://www.w3.org/2001/XMLSchema#string

Maurizio Scarpa

http://www.w3.org/2001/XMLSchema#string

Paul R Harmatz

http://www.w3.org/2001/XMLSchema#string

Roberto Giugliani

http://www.w3.org/2001/XMLSchema#string

William C Roberts

http://www.w3.org/2001/XMLSchema#string

P2860

ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography

Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and

A Rare Disease in Two Brothers

Newborn screening of lysosomal storage disorders

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

Clinical and biochemical manifestations of hyaluronidase deficiency

A clinical study of 77 patients with mucopolysaccharidosis type II

Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Valvular heart disease: diagnosis and management

Versican undergoes specific alterations in the fine molecular structure and organization in human aneurysmal abdominal aortas.

P2888

s10545-011-9359-8

P304

1183-1197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10545-011-9359-8

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51481619

http://www.w3.org/2001/XMLSchema#string

P698

21744090

http://www.w3.org/2001/XMLSchema#string

P921

heart valve disease

Angliavandeniai

mucopolysaccharidosis

P932

3228957

http://www.w3.org/2001/XMLSchema#string